Neurocrine(NBIX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance ® INGREZZA (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-OverYear Growth INGREZZA (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion ® Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, October 30, 2024 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended ...